Thanks Kelt. I am wondering if the estimates where rooted in examples of how the market has valued the other psoriasis drugs against the percentage of market share they have captured, or if he/she just looked at the percentage increase of the stocks after partnership/buyout. Either way I am hoping for the best result, but will still be satisfied if we get a good result, considering this is our darkhorse drug candidate.